Skip to main content

Resource Download
BMS, Roche, AZ Lose Out as China Favors Domestic Companies in 2020 NRDL PD-1 Battle

In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL).

This year, PD-1 inhibitors — a category of drugs that are often costly yet highly effective — were the hot issue between multinational corporations (MNCs) and domestic businesses. When the negotiations came to a close, home-grown PD-1 efforts from Shanghai Junshi Biosciences, BeiGene Ltd. and Jiangsu Hengrui Medicine took the coveted spots from household names like Roche, Bristol Myers Squibb, AstraZeneca and MSD.

Download your copy

EPP Pricing Platform will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy page.